RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - A phase II study

BMC Cancer

Volumn 9, Issue , 2009, Pages 308-

  Beier, Christoph P ^a   Schmid, Christina ^a   Gorlia, Thierry ^b   Kleinletzenberger, Christine ^a   Beier, Dagmar ^a   Grauer, Oliver ^a   Steinbrecher, Andreas ^a   Hirschmann, Birgit ^a   Brawanski, Alexander ^a   Dietmaier, Christopher ^c   Jauch Worley, Tanja ^a   Kölbl, Oliver ^a   Pietsch, Torsten ^d   Proescholdt, Martin ^a   Rümmele, Petra ^e   Muigg, Armin ^f   Stockhammer, Günther ^f   Hegi, Monika ^g   Bogdahn, Ulrich ^a   Hau, Peter ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b EORTC DATA CENTER   (Belgium)

^c Werkstofftechnologie   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e Department of Pathology ^*  (Germany)

^f UNIVERSITY OF INNSBRUCK   (Austria)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; GASTRITIS; GLIOBLASTOMA; HAND FOOT SYNDROME; HERPES SIMPLEX; HUMAN; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; RADIATION SICKNESS; SKIN ANAPHYLAXIS; SKIN EDEMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; YOUNG ADULT;

EID: 70349881482     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-308     Document Type: Article

References (27)

1. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572-2578.
2. Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
3. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008, 68:5706-5715. 10.1158/0008-5472.CAN-07-6878, 18632623.
4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
5. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 1999, 125:481-486. 10.1007/s004320050305, 10480340.
6. Neuwelt EA, Pagel M, Barnett P, Glassberg M, Frenkel EP. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Res 1981, 41:4466-4470.
7. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 1995, 83:1029-1037. 10.3171/jns.1995.83.6.1029, 7490617.
8. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36. 10.1002/cncr.10201, 11815957.
9. Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998, 4:499-505.
10. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W, Bogdahn U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001, 92:1936-1942. 10.1002/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H, 11745268.
11. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004, 100:1199-1207. 10.1002/cncr.20073, 15022287.
12. Chua SL, Rosenthal MA, Wong SS, Ashley DM, Woods AM, Dowling A, Cher LM. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol 2004, 6:38-43. 10.1215/S1152851703000188, 1871967, 14769139.
13. Glas M, Koch H, Hirschmann B, Jauch T, Steinbrecher A, Herrlinger U, Bogdahn U, Hau P. Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 2007, 72:302-307. 10.1159/000113052, 18198491.
14. Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, Rauch M, Brenner A, Rieckmann P, Schuth J. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007, 68:688-690. 10.1212/01.wnl.0000255937.27012.ee, 17325277.
15. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
16. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008, 10:332-337. 10.2353/jmoldx.2008.070169, 2438202, 18556773.
17. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998, 4:1567-1571.
18. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology 1997, 48:1336-1340.
19. Remlinger KA. Cutaneous reactions to chemotherapy drugs: the art of consultation. Arch Dermatol 2003, 139:77-81. 10.1001/archderm.139.1.77, 12533171.
20. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047. 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z, 10964334.
21. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000, 83:1281-1286. 10.1054/bjoc.2000.1459, 11044350.
22. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997, 54(Suppl 4):15-21. 10.2165/00003495-199700544-00005, 9361957.
23. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006, 24:4412-4417. 10.1200/JCO.2006.06.9104, 16983109.
24. ClinicalTrials.gov - a service of the U.S. National Institutes of Health. , http://www.clinicaltrials.gov
25. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007, 25:3357-3361. 10.1200/JCO.2007.10.7722, 17664483.
26. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007, 25:1470-1475. 10.1200/JCO.2006.07.4807, 17442989.
27. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008, 17:1225-1235. 10.1517/13543784.17.8.1225, 18616418.